These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications. Marginean EC; Melosky B Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791 [TBL] [Abstract][Full Text] [Related]
5. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy. Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906 [TBL] [Abstract][Full Text] [Related]
6. Immunomodulation in colorectal cancer: disappointment or promise? Pentheroudakis G; Pavlidis N Ann Oncol; 2003 Mar; 14(3):349-51. PubMed ID: 12598336 [No Abstract] [Full Text] [Related]
7. Colorectal cancer vaccines: Tumor-associated antigens Wagner S; Mullins CS; Linnebacher M World J Gastroenterol; 2018 Dec; 24(48):5418-5432. PubMed ID: 30622371 [TBL] [Abstract][Full Text] [Related]
8. The potential role of immunotherapy to treat colorectal cancer. Amin M; Lockhart AC Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074 [TBL] [Abstract][Full Text] [Related]
13. [MSI Status in Colorectal Cancer]. Mishima S; Yoshino T Gan To Kagaku Ryoho; 2018 Nov; 45(11):1567-1572. PubMed ID: 30449839 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for colorectal cancer. Koido S; Ohkusa T; Homma S; Namiki Y; Takakura K; Saito K; Ito Z; Kobayashi H; Kajihara M; Uchiyama K; Arihiro S; Arakawa H; Okamoto M; Gong J; Tajiri H World J Gastroenterol; 2013 Dec; 19(46):8531-42. PubMed ID: 24379570 [TBL] [Abstract][Full Text] [Related]
15. Results and challenges of immune checkpoint inhibitors in colorectal cancer. Emambux S; Tachon G; Junca A; Tougeron D Expert Opin Biol Ther; 2018 May; 18(5):561-573. PubMed ID: 29471676 [TBL] [Abstract][Full Text] [Related]
16. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates. Guo M; You C; Dou J Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347 [TBL] [Abstract][Full Text] [Related]
17. The colorectal cancer immune microenvironment and approach to immunotherapies. Koi M; Carethers JM Future Oncol; 2017 Aug; 13(18):1633-1647. PubMed ID: 28829193 [No Abstract] [Full Text] [Related]
18. Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions. Hilgenfeld RU; Kreuser ED Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():217-40. PubMed ID: 8815007 [No Abstract] [Full Text] [Related]
19. Current advancements and future perspectives of immunotherapy in colorectal cancer research. Kishore C; Bhadra P Eur J Pharmacol; 2021 Feb; 893():173819. PubMed ID: 33347822 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in human colorectal cancer: Challenges and prospective. Sun X; Suo J; Yan J World J Gastroenterol; 2016 Jul; 22(28):6362-72. PubMed ID: 27605872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]